**Core Concept**
Pyloric stenosis is a condition characterized by narrowing of the pyloric canal, leading to gastric outlet obstruction in infants. This condition is often associated with hyperplasia of the smooth muscle in the pyloric region. The underlying cause is thought to be an imbalance in the regulation of smooth muscle growth and development.

**Why the Correct Answer is Right**
The correct answer is Omeprazole, a proton pump inhibitor (PPI). Omeprazole has been linked to an increased risk of pyloric stenosis in infants. This is thought to be due to the suppression of gastric acid secretion, which in turn leads to an increase in gastric pH and an imbalance in the regulation of smooth muscle growth and development in the pyloric region. The exact mechanism is not fully understood, but it is believed to involve changes in the expression of growth factors and other signaling molecules that regulate smooth muscle growth.

**Why Each Wrong Option is Incorrect**
**Option A:** Metoclopramide - Metoclopramide is a prokinetic agent that is actually used to treat symptoms of gastroparesis, including delayed gastric emptying. It is not associated with an increased risk of pyloric stenosis.
**Option B:** Ranitidine - Ranitidine is an H2 receptor antagonist that is used to reduce gastric acid secretion. Like omeprazole, it can increase the risk of pyloric stenosis in infants, but it is not the correct answer.
**Option C:** Domperidone - Domperidone is a dopamine antagonist that is used to treat nausea and vomiting. It is not associated with an increased risk of pyloric stenosis.

**Clinical Pearl / High-Yield Fact**
Infants exposed to PPIs, such as omeprazole, in the first few weeks of life have an increased risk of developing pyloric stenosis. This is a rare but serious complication that requires prompt medical attention.

**Correct Answer:** B.